Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel Free GRDX Stock Alerts

Entero Therapeutics (GRDX) Competitors

$3.87 +0.23 (+6.32%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$3.90 +0.03 (+0.90%)
As of 05/15/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GRDX vs. INCR, NBRV, ZYBT, TELO, and LITS

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include InterCure (INCR), Nabriva Therapeutics (NBRV), Zhengye Biotechnology (ZYBT), Telomir Pharmaceuticals (TELO), and Lite Strategy (LITS). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to InterCure?

InterCure (NASDAQ:INCR) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

8.3% of InterCure shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, InterCure had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for InterCure and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat InterCure's score of 0.43 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
InterCure Neutral
Entero Therapeutics Very Positive

Entero Therapeutics has lower revenue, but higher earnings than InterCure. Entero Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterCure$270.20M0.17-$10.37M$0.0327.33
Entero Therapeutics$40K325.08-$6.39M-$1.69N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InterCure
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

InterCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

InterCure's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
InterCureN/A N/A N/A
Entero Therapeutics N/A -60.44%-7.05%

Summary

InterCure beats Entero Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to Nabriva Therapeutics?

Nabriva Therapeutics (NASDAQ:NBRV) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Entero Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Entero Therapeutics' return on equity of -60.44% beat Nabriva Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nabriva Therapeutics-148.11% -365.53% -135.81%
Entero Therapeutics N/A -60.44%-7.05%

In the previous week, Entero Therapeutics had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for Nabriva Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Nabriva Therapeutics' score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Nabriva Therapeutics Neutral
Entero Therapeutics Very Positive

Entero Therapeutics has lower revenue, but higher earnings than Nabriva Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A
Entero Therapeutics$40K325.08-$6.39M-$1.69N/A

Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Entero Therapeutics beats Nabriva Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Zhengye Biotechnology's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zhengye BiotechnologyN/A N/A N/A
Entero Therapeutics N/A -60.44%-7.05%

In the previous week, Zhengye Biotechnology had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Zhengye Biotechnology and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Zhengye Biotechnology's score of 1.44 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Zhengye Biotechnology Positive
Entero Therapeutics Very Positive

Zhengye Biotechnology has a beta of -2.47, suggesting that its stock price is 347% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Entero Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zhengye Biotechnology$116.36M0.39-$9.98MN/AN/A
Entero Therapeutics$40K325.08-$6.39M-$1.69N/A

12.3% of Entero Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zhengye Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Entero Therapeutics beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Entero Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Entero Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.33N/A
Entero Therapeutics$40K325.08-$6.39M-$1.69N/A

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Telomir Pharmaceuticals' score of 1.63 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Telomir Pharmaceuticals Very Positive
Entero Therapeutics Very Positive

Entero Therapeutics' return on equity of -60.44% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -206.92% -177.69%
Entero Therapeutics N/A -60.44%-7.05%

Telomir Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

12.3% of Entero Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Entero Therapeutics beats Telomir Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to Lite Strategy?

Lite Strategy (NASDAQ:LITS) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 1.6% of Lite Strategy shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Lite Strategy had 3 more articles in the media than Entero Therapeutics. MarketBeat recorded 4 mentions for Lite Strategy and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Lite Strategy's score of 0.98 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Lite Strategy Positive
Entero Therapeutics Very Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lite Strategy
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Entero Therapeutics' return on equity of -60.44% beat Lite Strategy's return on equity.

Company Net Margins Return on Equity Return on Assets
Lite StrategyN/A -90.81% -89.33%
Entero Therapeutics N/A -60.44%-7.05%

Lite Strategy has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Entero Therapeutics has higher revenue and earnings than Lite Strategy. Entero Therapeutics is trading at a lower price-to-earnings ratio than Lite Strategy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lite StrategyN/AN/A-$15.94M-$1.33N/A
Entero Therapeutics$40K325.08-$6.39M-$1.69N/A

Summary

Lite Strategy and Entero Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRDX vs. The Competition

Export
MetricEntero TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$12.24M$943.74M$4.74B$12.48B
Dividend YieldN/A4.84%5.93%5.25%
P/E Ratio-2.291.4822.9225.24
Price / Sales325.08119.26115.0182.25
Price / CashN/A20.0750.1456.04
Price / Book0.528.3538.266.90
Net Income-$6.39M-$2.97M$113.55M$334.66M
7 Day Performance13.16%8.49%2.46%0.13%
1 Month Performance58.61%83.71%4.53%1.11%
1 Year PerformanceN/A144.10%16.78%30.62%

Entero Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRDX
Entero Therapeutics
0.8595 of 5 stars		$3.87
+6.3%		N/AN/A$12.24M$40KN/A9
INCR
InterCure
0.8201 of 5 stars		$0.84
-0.3%		N/A-45.7%$45.87M$270.20M27.96350
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59MN/A70
ZYBT
Zhengye Biotechnology
1.0997 of 5 stars		$0.99
+0.8%		N/A-87.5%$45.00M$116.36MN/A278
TELO
Telomir Pharmaceuticals
1.53 of 5 stars		$1.30
-1.5%		N/A-46.6%$44.70MN/AN/A1

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GRDX) was last updated on 5/16/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel